Symbols

MDGL

Madrigal·NASDAQ

--(--)

MDGL fundamentals

MDGL Q4 2025 Earnings

Madrigal (MDGL) released its earnings on Feb 19, 2026: revenue was 321.10M (YoY +210.78%), beat estimates; EPS was -2.57 (YoY +5.17%), missed estimates.

Revenue / YoY

321.10M

+210.78%

EPS / YoY

-2.57

+5.17%

Report date

Feb 19, 2026

MDGL Earnings Call Summary for Q4,2025

Revenue Growth: Full year 2025 net sales of $958M, with Q4 at $321M, driven by Rezdiffra's U.S. MASH launch.
Pipeline Expansion: 10+ programs, including oral GLP-1, DGAT-2 inhibitor, and 6 siRNA assets, to complement Rezdiffra.
F4c Strategy: 2027 F4c full approval filing with 2-year open-label data showing 65% CSPH patients improved.
Financial Resilience: 2026 gross-to-net in high 30s, cash balance of $988M, and robust sales growth despite Q1 seasonal effects.

Earnings

EPS

Revenue

Revenue & Expenses

MDGL has released its 2025 Q4 earnings report, with revenue of 321.08M, reflecting a YoY change of 210.77%, and net profit of -58.58M, showing a YoY change of 1.42%. The Sankey diagram below clearly presents MDGL's revenue sources and cost distribution.

Key Indicators

Madrigal (MDGL) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Madrigal (MDGL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Madrigal (MDGL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Madrigal (MDGL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown